KCPG
PBYI icon

Kavar Capital Partners Group’s Puma Biotechnology PBYI Stock Holding History

Kavar Capital Partners Group’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-2
Closed – – 348
2014
Q1 		$0 Buy
+2
New +$235 ﹤0.01% 563

Other funds holding PBYI

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Kavar Capital Partners Group's PBYI Position: Q2 2014 in Review

Kavar Capital Partners Group sold out of Puma Biotechnology (PBYI) in Q2 2014, closing a stake of 2 shares.

Kavar Capital Partners Group first reported a position in PBYI in Q1 2014 and held it in 1 quarter. The position peaked at $0 in Q1 2014. 137 funds tracked by Wall St. Rank hold PBYI as of Q2 2014.

  • Kavar Capital Partners Group reported no remaining Puma Biotechnology position as of Q2 2014 after selling out during the quarter.
  • Kavar Capital Partners Group sold 2 Puma Biotechnology shares in Q2 2014.
  • Kavar Capital Partners Group first reported a position in Puma Biotechnology in Q1 2014 and held it in 1 quarter.
  • Kavar Capital Partners Group's Puma Biotechnology position peaked at $0 in Q1 2014.
  • 137 funds tracked by Wall St. Rank held Puma Biotechnology as of Q2 2014.

Based on Kavar Capital Partners Group's 13F filing for Q2 2014, filed 25 Jan 2019.